Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
EJNMMI Res. 2025-04-09; 15(1):
DOI: 10.1186/s13550-025-01232-8
Lire sur PubMed
1. EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8.
Prostate-specific membrane antigen (PSMA) expression in primary and metastatic
renal cell cancer (UroCCR-65 study).
Binzaqr S(1), Kryza D(2)(3), Giraudet AL(2), Bernhard JC(4)(5), Gross-Goupil
M(4), Yacoub M(6), Margue G(4)(5), Hindié E(1)(7)(8), Morgat C(9)(10).
Author information:
(1)Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux,
F-33076, France.
(2)Univ. Lyon – Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRS,
Villeurbanne, F-69100, France.
(3)Léon Bérard Comprehensive Cancer center, Nuclear medicine department LUMEN,
15 rue Gabriel Sarrazin, cedex 08, Lyon, F-69373, France.
(4)Department of Urology, University Hospital of Bordeaux, Bordeaux, F-33076,
France.
(5)I. Care Bordeaux, University of Bordeaux, Bordeaux, F-33076, France.
(6)Department of Pathology, University Hospital of Bordeaux, Bordeaux, F-33076,
France.
(7)University of Bordeaux, UMR CNRS 5287, INCIA, Talence, F-33400, France.
(8)Institut Universitaire de France (IUF), Paris, F-75000, France.
(9)Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux,
F-33076, France. .
(10)University of Bordeaux, UMR CNRS 5287, INCIA, Talence, F-33400, France.
.
BACKGROUND: Prostate-specific membrane antigen (PSMA) has been shown to be
overexpressed in the neo-vasculature of renal cancers. However, studies
investigating the pattern of PSMA expression in primary RCC and RCC metastases
according to metastatic sites are rare. 44 frozen samples of RCC, 19 primaries
(9 clear cell (cc) RCC, 7 papillary (pap) RCC, and 3 chromophobe (ch) RCC) and
25 (24 samples have ccRCC histology and one is unclassified) unpaired metastases
(8 from adrenals, 8 from bones, 2 from lungs, 2 from liver and 5 others (1 lymph
node, 1 pancreas, 1 brain, 1 gallbladder and 1 muscle)), were available from the
UroCCR project (NCT03293563). PSMA expression was assessed by autoradiography
using [177Lu]Lu-PSMA-617 as binding agent and the specific binding (total
binding-non-specific binding) was calculated and expressed as a percentage of
total binding. A patient suffering from metastatic ccRCC was also administered
[68Ga]Ga-PSMA-11 to evaluate PSMA expression.
RESULTS: The mean specific binding was 28.9 ± 40.4% for primary renal cancer and
65.0 ± 38.9% for metastasis. Regarding histology, high PSMA expression was
depicted in 33.3% of ccRCC, 33.3% of chRCC and 57.1% of papRCC. PSMA was more
frequently expressed in primary samples of papRCC histology with renal capsule
invasion (p = 0.0286). A higher PSMA-specific binding and a higher number of
samples with high PSMA-expression were depicted in metastatic samples. Bone
metastasis showed lower binding than other metastatic sites combined
(p = 0.0005). The patient suffering from metastatic ccRCC showed high
[68Ga]Ga-PSMA-11 uptake on known distant metastases and additional site
uncovered.
CONCLUSION: PSMA showed high expression in metastases of ccRCC.
CLINICAL TRIAL REGISTRATION: NCT, NCT03293563, prospectively registered
September 20, 2017, http://www.
CLINICALTRIALS: gov .
© 2025. The Author(s).
DOI: 10.1186/s13550-025-01232-8
PMCID: PMC11981970
PMID: 40205264
Conflict of interest statement: Declarations. Ethics approval and consent to
participate: The UroCCR project (NCT03293563), which is IRB-approved and has the
CNIL authorization number DR-2013-206. The UroCCR database received approval
from Comité de Protection des Personnes Sud-Ouest et Outre-mer III (DC 2012/108)
and favorable opinion of the Comité Consultatif sur le Traitement de
l’Information en matière de Recherche dans le domaine de la Santé (CCTIRS).
Consent for publication: Written informed consent was obtained for publication.
Competing interests: The authors have no relevant financial or non-financial
interests to disclose.